Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Zappasodi

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Blood|August 24, 2011
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic targetRoberta Zappasodi, Italia Bongarzone, Gaia C Ghedini, et al.
International Journal of Cancer|March 21, 2014
Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomasRoberta Zappasodi, Alessandra Cavanè, Marilena V Iorio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid TumorsOmid Hamid, Dana B Cardin, F Stephen Hodi, et al.
Blood|January 10, 2015
HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphomaRoberta Zappasodi, Giusi Ruggiero, Carla Guarnotta, et al.
Cell Reports|January 13, 2021
Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of MelanomaSadna Budhu, Rachel Giese, Aditi Gupta, et al.
Life Science Alliance|October 27, 2023
APR-246 increases tumor antigenicity independent of p53Judith Michels, Divya Venkatesh, Cailian Liu, et al.
Journal for Immunotherapy of Cancer|June 15, 2021
Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cellsGiovanni Fucà, Margherita Ambrosini, Luca Agnelli, et al.
Cancer Cell|June 13, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade ActivityRoberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Cancer Research|August 29, 2014
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumabLorenzo Castagnoli, Manuela Iezzi, Gaia C Ghedini, et al.
Cancer Cell|October 10, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade ActivityRoberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Blood|August 24, 2011
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic targetRoberta Zappasodi, Italia Bongarzone, Gaia C Ghedini, et al.
International Journal of Cancer|March 21, 2014
Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomasRoberta Zappasodi, Alessandra Cavanè, Marilena V Iorio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid TumorsOmid Hamid, Dana B Cardin, F Stephen Hodi, et al.
Blood|January 10, 2015
HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphomaRoberta Zappasodi, Giusi Ruggiero, Carla Guarnotta, et al.
Cell Reports|January 13, 2021
Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of MelanomaSadna Budhu, Rachel Giese, Aditi Gupta, et al.
Life Science Alliance|October 27, 2023
APR-246 increases tumor antigenicity independent of p53Judith Michels, Divya Venkatesh, Cailian Liu, et al.
Journal for Immunotherapy of Cancer|June 15, 2021
Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cellsGiovanni Fucà, Margherita Ambrosini, Luca Agnelli, et al.
Cancer Cell|June 13, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade ActivityRoberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Cancer Research|August 29, 2014
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumabLorenzo Castagnoli, Manuela Iezzi, Gaia C Ghedini, et al.
Cancer Cell|October 10, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade ActivityRoberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Pageof 7